Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints
Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapy
New Drug Application (NDA) submissions targeted for Q4 2021
FLORHAM PARK, N.J., April 29,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Helicobacter Pylori | New Drug Applications | Pharmaceuticals | Proton Pump Inhibitors PPIs | Study